<DOC>
	<DOCNO>NCT00000713</DOCNO>
	<brief_summary>To determine safety ampligen several dos HIV-infected patient yet develop AIDS advance AIDS relate complex ( ARC ) . Biologic , antiviral , immunologic effect study . Evidence indicate long period symptom follow infection HIV . Individuals infect virus could benefit therapy drug act kill virus stimulate immune system individual . The immune system mean human body fight infection . Ampligen suitable drug clinical trial HIV show stimulate immune system inhibit HIV vitro ( test tube ) drug level achieve without noticeable clinical side effect .</brief_summary>
	<brief_title>A Phase I Clinical Trial To Evaluate Toxicity , Antiviral Immunomodulatory Effects Range Doses Ampligen HIV-Infected Subjects</brief_title>
	<detailed_description>Evidence indicate long period symptom follow infection HIV . Individuals infect virus could benefit therapy drug act kill virus stimulate immune system individual . The immune system mean human body fight infection . Ampligen suitable drug clinical trial HIV show stimulate immune system inhibit HIV vitro ( test tube ) drug level achieve without noticeable clinical side effect . Individuals enter study give ampligen intravenous infusion first week trial twice week follow 8 week . The dose individual receives determine response earlier individual . Each follow 12 week last dose ampligen give . Each individual maintains daily diary listing symptom problem occur , headache , nausea , change appetite . Other anti-HIV drug take trial , aspirin acetaminophen take 2 hour without consult research staff . Blood drawn interval trial follow-up use determine effect ampligen HIV immune system well monitor toxicity side effect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>poly ( I ) .poly ( c12 , U )</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Shortcourse therapy ( 7 day ) oral acyclovir ketoconazole . Patients must : Evidence HIV infection measure confirmed positive antibody test . A confirmed pending HIV blood culture , serum p24 antigen test . The ELISA test confirm licensed Western blot analysis asymptomatic . Exclusion Criteria Concurrent Medication : Excluded : Aspirin acetaminophen beyond 72 hour without contact investigator . Chemoprophylaxis Pneumocystis carinii pneumonia ( PCP ) . Patients follow exclude : AIDS . AIDS relate symptom advanced ARC &lt; 200 CD4 cells/mm3 least two follow : Weight loss excess 10 lb 10 percent body weight within 6month interval . Temperature &gt; 38.5 degree C without night sweat , persist 14 consecutive day 15 day 30day interval . Diarrhea define = &gt; 3 liquid stool per day , persist 30 day without definable cause . Recurrent oral candidiasis document morphology response antifungal therapy . Patients active oral candidiasis time entry study ; must free candidiasis baseline 1 enrollment . Multidermatomal herpes zoster within past 2 year . Hairy leukoplakia within past 3 year . Prior Medication : Excluded within 14 day study entry : Other biologic response modifier . Corticosteroids . Systemic antibiotic . Excluded within 30 day study entry : Other antiretroviral agent . Excluded within 60 day study entry : Ribavirin . Zidovudine . Concurrent neoplasms basal cell carcinoma skin . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Polyribonucleotides</keyword>
	<keyword>HIV Seropositivity</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>ampligen</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>